LATHAM, N.Y. --(BUSINESS WIRE)--Jun. 3, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it closed the previously announced sale of its NAMIC ® fluid

LATHAM, N.Y. --(BUSINESS WIRE)--May 28, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that representatives of the Company will ring the NASDAQ Stock

LATHAM, N.Y. --(BUSINESS WIRE)--May 22, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the United States Food and Drug Administration ( FDA )

LATHAM, N.Y. --(BUSINESS WIRE)--May 13, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced enrollment of the first patient in its NanoKnife ® Irreversible

AngioDynamics to host conference call today at 5:00 p.m. ET LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 17, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for oncology, vascular access, and peripheral vascular disease, today announced that

LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 17, 2019-- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the Company received central Institutional Review Board (IRB)

Fiscal 2019 Third Quarter Highlights Net sales of $86.3 million , an increase of 3.0% year over year Gross margin declined 10 basis points year over year to 54.1% GAAP EPS of $0.02 per share; adjusted EPS of $0.19 per share Cash provided by operations of $8.3 million ; capital expenditures of $0.9

LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 1, 2019-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Michael C. Greiner , Executive Vice President and Chief

LATHAM, N.Y. --(BUSINESS WIRE)--Apr. 1, 2019-- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced that the United States Food and Drug Administration ( FDA ) approved

LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 28, 2019-- Second paragraph, first sentence of release should read: The additional indications clear the OARtrac System for use with patient-specific, pre-calibrated Plastic Scintillating Detector (PSD) sensors used during cancer treatments to measure photon and

LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 12, 2019-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the third quarter of

LATHAM, N.Y. --(BUSINESS WIRE)--Mar. 8, 2019-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced that the United States District Court for the District of Delaware ,

LATHAM, N.Y. --(BUSINESS WIRE)--Feb. 26, 2019-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, and

Fiscal 2019 Second Quarter Highlights Net sales of $91.5 million , an increase of 5.5% year over year Gross margin expanded 440 basis points year over year to 53.7% GAAP EPS of $0.06 per share; adjusted EPS of $0.22 per share Cash provided by operations of $13.0 million ; capital expenditures of

LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 20, 2018-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer , President and Chief Executive Officer, and

LATHAM, N.Y. --(BUSINESS WIRE)--Dec. 10, 2018-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the second quarter of

Fiscal 2019 First Quarter Highlights Net sales of $85.3 million , flat versus prior year Gross margin expanded 380 basis points year over year to 52.1% GAAP EPS of $(0.01) per share; adjusted EPS of $0.16 per share Cash used in operations of $8.9 million ; capital expenditures of $0.7 million

LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 19, 2018-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Michael C. Greiner , Executive Vice President and Chief

LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 13, 2018-- AngioDynamics, Inc.  (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the first quarter of

LATHAM, N.Y. --(BUSINESS WIRE)--Sep. 13, 2018-- AngioDynamics, Inc. (NASDAQ:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease and oncology, today announced an agreement to acquire RadiaDyne, a privately held medical